Dixon Hubard Feinour & Brown’s Novo Nordisk NVO Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7,670	Closed	-$206K	–	202
2017 Q4	$206K	Buy	+7,670	New	+$195K	0.06%	179
2016 Q4	–	Sell	-11,640	Closed	-$242K	–	180
2016 Q3	$242K	Sell	11,640 -430	-4%	-$10.7K	0.08%	149
2016 Q2	$325K	Hold	12,070	–	–	0.1%	131
2016 Q1	$337K	Sell	12,070 -2,500	-17%	-$67K	0.11%	131
2015 Q4	$423K	Buy	14,570 +520	+4%	+$14.4K	0.13%	118
2015 Q3	$381K	Buy	14,050 +1,388	+11%	+$39.3K	0.14%	116
2015 Q2	$347K	Sell	12,662 -3,788	-23%	-$106K	0.11%	130
2015 Q1	$439K	Hold	16,450	–	–	0.13%	121
2014 Q4	$348K	Buy	16,450 +2,200	+15%	+$49.1K	0.11%	132
2014 Q3	$339K	Buy	14,250 +3,880	+37%	+$89.3K	0.11%	132
2014 Q2	$239K	Hold	10,370	–	–	0.08%	172
2014 Q1	$237K	Buy	+10,370	New	+$221K	0.08%	167

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Dixon Hubard Feinour & Brown's NVO Position: Q1 2018 in Review

Dixon Hubard Feinour & Brown sold out of Novo Nordisk (NVO) in Q1 2018, closing a stake of 7,670 shares — an estimated $206K sold.

Dixon Hubard Feinour & Brown first reported a position in NVO in Q1 2014 and held it in 12 quarters. The position peaked at $439K in Q1 2015. 553 funds tracked by Wall St. Rank hold NVO as of Q1 2018.

Dixon Hubard Feinour & Brown reported no remaining Novo Nordisk position as of Q1 2018 after selling out during the quarter.
Dixon Hubard Feinour & Brown sold 7,670 Novo Nordisk shares in Q1 2018, an estimated $206K.
Dixon Hubard Feinour & Brown first reported a position in Novo Nordisk in Q1 2014 and held it in 12 quarters.
Dixon Hubard Feinour & Brown's Novo Nordisk position peaked at $439K in Q1 2015.
553 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2018.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q1 2018, filed 14 May 2018.